Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
Fuente:
arXiv
Saved in:
| Main Authors: | Hall, Andrew, Wilson, Duncan, Barber, Stuart, Brown, Sarah R |
|---|---|
| Format: | Preprint |
| Published: |
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
by: Andrew Hall, et al.
Published: (2026)
by: Andrew Hall, et al.
Published: (2026)
Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
by: Lee, Kyong Ju, et al.
Published: (2025)
by: Lee, Kyong Ju, et al.
Published: (2025)
BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
by: Chen, Yuxuan, et al.
Published: (2026)
by: Chen, Yuxuan, et al.
Published: (2026)
A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
by: Li, Yuhan, et al.
Published: (2024)
by: Li, Yuhan, et al.
Published: (2024)
Adaptive Weighting for Time-to-Event Continual Reassessment Method: Improving Safety in Phase I Dose-Finding Through Data-Driven Delay Distribution Estimation
by: Amevor, Robert, et al.
Published: (2026)
by: Amevor, Robert, et al.
Published: (2026)
Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
by: Sunami, Hisato, et al.
Published: (2024)
by: Sunami, Hisato, et al.
Published: (2024)
CUI-MET: Clinical Utility Index Dose Optimization Approach for Multiple-Dose, Multiple-Outcome Randomized Trial Designs
by: Zhang, Fanni, et al.
Published: (2025)
by: Zhang, Fanni, et al.
Published: (2025)
A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Komaki, Moka, et al.
Published: (2025)
by: Komaki, Moka, et al.
Published: (2025)
Feasible Dose-Response Curves for Continuous Treatments Under Positivity Violations
by: Bao, Han, et al.
Published: (2025)
by: Bao, Han, et al.
Published: (2025)
BMW: Bayesian Model-Assisted Adaptive Phase II Clinical Trial Design for Win Ratio Statistic
by: Zhu, Di, et al.
Published: (2026)
by: Zhu, Di, et al.
Published: (2026)
A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization
by: Gu, Xuemin, et al.
Published: (2026)
by: Gu, Xuemin, et al.
Published: (2026)
Power and Sample Size Calculations for Bayes Factors in two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)
by: Kelter, Riko
Published: (2026)
Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)
by: Kelter, Riko
Published: (2026)
A Fully Bayesian Approach for Comprehensive Mapping of Magnitude and Phase Brain Activation in Complex-Valued fMRI Data
by: Wang, Zhengxin, et al.
Published: (2024)
by: Wang, Zhengxin, et al.
Published: (2024)
Weighted Brier Score -- an Overall Summary Measure for Risk Prediction Models with Clinical Utility Consideration
by: Zhu, Kehao, et al.
Published: (2024)
by: Zhu, Kehao, et al.
Published: (2024)
A Pseudo-likelihood Approach to Under-5 Mortality Estimation
by: Okonek, Taylor, et al.
Published: (2023)
by: Okonek, Taylor, et al.
Published: (2023)
Standardized Descriptive Index for Measuring Deviation and Uncertainty in Psychometric Indicators
by: Muñoz, Mark Dominique Dalipe
Published: (2025)
by: Muñoz, Mark Dominique Dalipe
Published: (2025)
On Assessing Overall Survival (OS) in Oncology Studies
by: Hsu, Jason C.
Published: (2025)
by: Hsu, Jason C.
Published: (2025)
Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
by: Lotspeich, Sarah C., et al.
Published: (2026)
by: Lotspeich, Sarah C., et al.
Published: (2026)
MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials
by: Lyu, Jiaying, et al.
Published: (2020)
by: Lyu, Jiaying, et al.
Published: (2020)
Cumulative Logit Ordinal Regression with Proportional Odds under Nonignorable Missing Response -- Application to Phase III Trial
by: Maity, Arnab Kumar, et al.
Published: (2025)
by: Maity, Arnab Kumar, et al.
Published: (2025)
Distribution-Free Selection of Low-Risk Oncology Patients for Survival Beyond a Time Horizon
by: Sesia, Matteo, et al.
Published: (2025)
by: Sesia, Matteo, et al.
Published: (2025)
Considerations for the Integration of Randomized Controlled Trials and Real-World Data
by: Qiu, Sky, et al.
Published: (2026)
by: Qiu, Sky, et al.
Published: (2026)
Fiducial Confidence Intervals for Agreement Measures Among Raters Under a Generalized Linear Mixed Effects Model
by: Sahu, Soumya, et al.
Published: (2025)
by: Sahu, Soumya, et al.
Published: (2025)
Evaluating causal effects on time-to-event outcomes in an RCT in Oncology with treatment discontinuation
by: Ballerini, Veronica, et al.
Published: (2023)
by: Ballerini, Veronica, et al.
Published: (2023)
An Estimator-Robust Design for Augmenting Randomized Controlled Trial with External Real-World Data
by: Qiu, Sky, et al.
Published: (2025)
by: Qiu, Sky, et al.
Published: (2025)
Nonparametric Bayesian Multi-Treatment Mixture Cure Survival Model with Application in Pediatric Oncology
by: Chang, Peter, et al.
Published: (2025)
by: Chang, Peter, et al.
Published: (2025)
DEMO: Dose Exploration, Monitoring, and Optimization Using a Biological Mediator for Clinical Outcomes
by: Yang, Cheng-Han, et al.
Published: (2024)
by: Yang, Cheng-Han, et al.
Published: (2024)
The Backfill i3+3 Design for Dose-Finding Trials in Oncology
by: Liu, Jiaxin, et al.
Published: (2023)
by: Liu, Jiaxin, et al.
Published: (2023)
Utility-based optimization of Fujikawa's basket trial design -- Pre-specified protocol of a comparison study
by: Sauer, Lukas D, et al.
Published: (2024)
by: Sauer, Lukas D, et al.
Published: (2024)
Dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials
by: Silva, Rebecca B., et al.
Published: (2025)
by: Silva, Rebecca B., et al.
Published: (2025)
An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
by: Cui, Ying, et al.
Published: (2025)
by: Cui, Ying, et al.
Published: (2025)
Semi-partitioned Generalized Method of Moments for Longitudinal Data with Lagged and Feedback Covariates
by: Ramezani, Niloofar, et al.
Published: (2026)
by: Ramezani, Niloofar, et al.
Published: (2026)
Investigating the performance of the Phase II Hotelling T2 chart when monitoring multivariate time series observations
by: Nadi, Adel Ahmadi, et al.
Published: (2025)
by: Nadi, Adel Ahmadi, et al.
Published: (2025)
Bayesian calendar-time survival analysis with epidemic curve priors and variant-specific infection hazards
by: Dahl, Angela M, et al.
Published: (2026)
by: Dahl, Angela M, et al.
Published: (2026)
Evaluating Bias Reduction Methods in Binary Emax Model for Reliable Dose-Response Estimation
by: Zhang, Jiangshan, et al.
Published: (2025)
by: Zhang, Jiangshan, et al.
Published: (2025)
HAL-Based Plug-in Estimation with Pointwise Asymptotic Normality of the Causal Dose-Response Curve
by: Shi, Junming, et al.
Published: (2024)
by: Shi, Junming, et al.
Published: (2024)
Hybrid Non-informative and Informative Prior Model-assisted Designs for Mid-trial Dose Insertion
by: Yamada, Kana, et al.
Published: (2026)
by: Yamada, Kana, et al.
Published: (2026)
Robust Emax Model Fitting: Addressing Nonignorable Missing Binary Outcome in Dose-Response Analysis
by: Zhang, Jiangshan, et al.
Published: (2024)
by: Zhang, Jiangshan, et al.
Published: (2024)
Mixture of Finite Mixtures Model for Basket Trial
by: Geng, Junxian, et al.
Published: (2020)
by: Geng, Junxian, et al.
Published: (2020)
Similar Items
-
Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
by: Andrew Hall, et al.
Published: (2026) -
Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
by: Lee, Kyong Ju, et al.
Published: (2025) -
BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
by: Chen, Yuxuan, et al.
Published: (2026) -
A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
by: Li, Yuhan, et al.
Published: (2024) -
Adaptive Weighting for Time-to-Event Continual Reassessment Method: Improving Safety in Phase I Dose-Finding Through Data-Driven Delay Distribution Estimation
by: Amevor, Robert, et al.
Published: (2026)